IL111291A - Use of 2 Phenyl - 3 Aroylbenzoins in Japan in the preparation of cartilage screening inhibitors - Google Patents

Use of 2 Phenyl - 3 Aroylbenzoins in Japan in the preparation of cartilage screening inhibitors

Info

Publication number
IL111291A
IL111291A IL11129194A IL11129194A IL111291A IL 111291 A IL111291 A IL 111291A IL 11129194 A IL11129194 A IL 11129194A IL 11129194 A IL11129194 A IL 11129194A IL 111291 A IL111291 A IL 111291A
Authority
IL
Israel
Prior art keywords
compound
cartilage degradation
formula
phenyl
preparation
Prior art date
Application number
IL11129194A
Other languages
English (en)
Hebrew (he)
Other versions
IL111291A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL111291A0 publication Critical patent/IL111291A0/xx
Publication of IL111291A publication Critical patent/IL111291A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL11129194A 1993-10-15 1994-10-13 Use of 2 Phenyl - 3 Aroylbenzoins in Japan in the preparation of cartilage screening inhibitors IL111291A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,531 US5418252A (en) 1993-10-15 1993-10-15 Method for inhibiting cartilage degradation

Publications (2)

Publication Number Publication Date
IL111291A0 IL111291A0 (en) 1994-12-29
IL111291A true IL111291A (en) 1999-01-26

Family

ID=22477856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11129194A IL111291A (en) 1993-10-15 1994-10-13 Use of 2 Phenyl - 3 Aroylbenzoins in Japan in the preparation of cartilage screening inhibitors

Country Status (22)

Country Link
US (1) US5418252A (ja)
EP (1) EP0652002B1 (ja)
JP (1) JPH07188013A (ja)
KR (1) KR950010887A (ja)
CN (1) CN1053102C (ja)
AT (1) ATE199642T1 (ja)
AU (1) AU676375B2 (ja)
CA (1) CA2118094A1 (ja)
CZ (1) CZ253494A3 (ja)
DE (1) DE69426855T2 (ja)
DK (1) DK0652002T3 (ja)
ES (1) ES2154669T3 (ja)
GR (1) GR3035864T3 (ja)
HU (1) HUT71249A (ja)
IL (1) IL111291A (ja)
NO (1) NO943873L (ja)
NZ (1) NZ264672A (ja)
PH (1) PH31316A (ja)
PT (1) PT652002E (ja)
RU (1) RU94037246A (ja)
SI (1) SI0652002T1 (ja)
ZA (1) ZA948028B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
EP1546138B1 (en) * 2002-09-30 2012-01-18 A/S GEA Farmaceutisk Fabrik Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CN1053102C (zh) 2000-06-07
US5418252A (en) 1995-05-23
IL111291A0 (en) 1994-12-29
NO943873L (no) 1995-04-18
PH31316A (en) 1998-07-06
EP0652002B1 (en) 2001-03-14
HUT71249A (en) 1995-11-28
NZ264672A (en) 1997-06-24
JPH07188013A (ja) 1995-07-25
ES2154669T3 (es) 2001-04-16
AU676375B2 (en) 1997-03-06
GR3035864T3 (en) 2001-08-31
DE69426855T2 (de) 2001-08-30
DE69426855D1 (de) 2001-04-19
NO943873D0 (no) 1994-10-13
PT652002E (pt) 2001-06-29
CN1106260A (zh) 1995-08-09
CZ253494A3 (en) 1995-05-17
AU7578994A (en) 1995-05-04
KR950010887A (ko) 1995-05-15
ZA948028B (en) 1996-04-15
CA2118094A1 (en) 1995-04-16
HU9402957D0 (en) 1995-02-28
RU94037246A (ru) 1996-11-10
EP0652002A1 (en) 1995-05-10
SI0652002T1 (en) 2001-06-30
ATE199642T1 (de) 2001-03-15
DK0652002T3 (da) 2001-04-17

Similar Documents

Publication Publication Date Title
US5418252A (en) Method for inhibiting cartilage degradation
EP0651999B1 (en) Methods of inhibiting uterine fibrosis
US5610166A (en) Methods for inhibiting angiogenesis
NZ264677A (en) Use of substituted benzothiophenes to prepare pharmaceutical compositions for inhibiting endometriosis
AU690595B2 (en) Method for increasing libido in post-menopausal women
EP0963756B1 (en) Inhibition of advanced glycosylation end products
EP0659413B1 (en) Inhibition of CNS problems in post-menopausal women
US5593987A (en) Methods of inhibiting breast disorders
US5550123A (en) Methods for inhibiting bone prosthesis degeneration
US5545641A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
EP0769945B1 (en) Use of 2-phenyl-3-aroylbenzothiophene derivatives for the manufacture of a medicament for bone healing and fracture repair
US5494929A (en) Methods of inhibiting growth hormone effects

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees